On July 4th, Gelunhui announced the performance forecast for the first half of 2024 of Micro-Electro-Physiology (688351.SH). According to preliminary calculations by the financial department, the company is expected to achieve revenue of 195 million yuan to 210 million yuan in the first half of 2024, an increase of 52.8773 million yuan to 67.8773 million yuan compared to the same period of the previous year (statutory disclosure data), a year-on-year increase of 37.21% to 47.76%.
The net income attributable to the owners of the parent company is expected to be 15 million yuan to 20 million yuan, an increase of RMB 12.8446 million yuan to RMB 17.8446 million yuan compared to the same period of the previous year (statutory disclosure data), a year-on-year increase of 595.92% to 827.89%.
The net income attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be 0.8 million yuan to 1.2 million yuan, an increase of RMB 13.1659 million yuan to RMB 13.5659 million yuan compared to the same period of the previous year (statutory disclosure data).
During the reporting period, the company continued to develop the field of cardiac electrophysiology, adhered to the global strategy, focused on the 'Ice and Fire' series of advantageous products, and vigorously entered the atrial fibrillation market, leading the overall promotion of domestic electrophysiological surgical solutions. The company's product structure was further optimized, with a significant increase in the proportion of sales of high-value consumables such as TrueForce pressure monitoring radiofrequency ablation catheters, IceMagic cryoablation series products, and FireMagic microelectrode radiofrequency ablation catheters, further improving the company's competitiveness in the electrophysiology market. In terms of overseas markets, the company continued to promote the brand influence of electrophysiological surgical solutions, improve penetration rate, continue to promote cooperation with high-quality customers worldwide and in regional markets, and promote the market access and promotion work of TrueForce pressure monitoring radiofrequency ablation catheters in European and other countries. During this reporting period, the company's main business development was in good shape, and overall sales in the first half of the year achieved rapid growth, driving a significant year-on-year increase in the company's net income.